These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X MAbs; 2021; 13(1):1953683. PubMed ID: 34313527 [TBL] [Abstract][Full Text] [Related]
5. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645 [TBL] [Abstract][Full Text] [Related]
6. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Rappazzo CG; Tse LV; Kaku CI; Wrapp D; Sakharkar M; Huang D; Deveau LM; Yockachonis TJ; Herbert AS; Battles MB; O'Brien CM; Brown ME; Geoghegan JC; Belk J; Peng L; Yang L; Hou Y; Scobey TD; Burton DR; Nemazee D; Dye JM; Voss JE; Gunn BM; McLellan JS; Baric RS; Gralinski LE; Walker LM Science; 2021 Feb; 371(6531):823-829. PubMed ID: 33495307 [TBL] [Abstract][Full Text] [Related]
7. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Kramer KJ; Johnson NV; Shiakolas AR; Suryadevara N; Periasamy S; Raju N; Williams JK; Wrapp D; Zost SJ; Walker LM; Wall SC; Holt CM; Hsieh CL; Sutton RE; Paulo A; Nargi RS; Davidson E; Doranz BJ; Crowe JE; Bukreyev A; Carnahan RH; McLellan JS; Georgiev IS Cell Rep; 2021 Oct; 37(1):109784. PubMed ID: 34592170 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2. Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671 [TBL] [Abstract][Full Text] [Related]
9. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572 [TBL] [Abstract][Full Text] [Related]
10. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray. Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808 [TBL] [Abstract][Full Text] [Related]
11. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Lorenzi JCC; Finkin S; Hägglöf T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ Cell; 2020 Aug; 182(4):828-842.e16. PubMed ID: 32645326 [TBL] [Abstract][Full Text] [Related]
12. Decay of Fc-dependent antibody functions after mild to moderate COVID-19. Lee WS; Selva KJ; Davis SK; Wines BD; Reynaldi A; Esterbauer R; Kelly HG; Haycroft ER; Tan HX; Juno JA; Wheatley AK; Hogarth PM; Cromer D; Davenport MP; Chung AW; Kent SJ Cell Rep Med; 2021 Jun; 2(6):100296. PubMed ID: 33997824 [TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L Cell Rep; 2021 Jul; 36(2):109353. PubMed ID: 34237283 [TBL] [Abstract][Full Text] [Related]
14. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Wec AZ; Wrapp D; Herbert AS; Maurer DP; Haslwanter D; Sakharkar M; Jangra RK; Dieterle ME; Lilov A; Huang D; Tse LV; Johnson NV; Hsieh CL; Wang N; Nett JH; Champney E; Burnina I; Brown M; Lin S; Sinclair M; Johnson C; Pudi S; Bortz R; Wirchnianski AS; Laudermilch E; Florez C; Fels JM; O'Brien CM; Graham BS; Nemazee D; Burton DR; Baric RS; Voss JE; Chandran K; Dye JM; McLellan JS; Walker LM Science; 2020 Aug; 369(6504):731-736. PubMed ID: 32540900 [TBL] [Abstract][Full Text] [Related]
15. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Tai W; Zhang X; He Y; Jiang S; Du L Antiviral Res; 2020 Jul; 179():104820. PubMed ID: 32405117 [TBL] [Abstract][Full Text] [Related]
17. Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody. Ng OW; Keng CT; Leung CS; Peiris JS; Poon LL; Tan YJ PLoS One; 2014; 9(7):e102415. PubMed ID: 25019613 [TBL] [Abstract][Full Text] [Related]
18. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Zhou Y; Liu Z; Li S; Xu W; Zhang Q; Silva IT; Li C; Wu Y; Jiang Q; Liu Z; Wang Q; Guo Y; Wu J; Gu C; Cai X; Qu D; Mayer CT; Wang X; Jiang S; Ying T; Yuan Z; Xie Y; Wen Y; Lu L; Wang Q Cell Rep; 2021 Feb; 34(5):108699. PubMed ID: 33485405 [TBL] [Abstract][Full Text] [Related]
20. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. Nguyen-Contant P; Embong AK; Kanagaiah P; Chaves FA; Yang H; Branche AR; Topham DJ; Sangster MY mBio; 2020 Sep; 11(5):. PubMed ID: 32978311 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]